Therapy of addition for Alzheimer's Disease: combination with galantamine and memantine

  • Julio Zarra1 and

    Affiliated with

    • Luisa Schmidt2

      Affiliated with

      Annals of General Psychiatry20109(Suppl 1):S118

      DOI: 10.1186/1744-859X-9-S1-S118

      Published: 22 April 2010


      The efficacy, safety, and tolerability of nootropic cholinergic agent: GALANTAMINE (with a dual mechanism of action on the cholinergic a system) and moderate affinity NMDA- receptor antagonist: MEMANTINE, were assessed taking into account the profile of patients with neurocognitive disorder: Alzheimer's disease, from the clinical aspects and the different classifications.

      Materials and methods

      The experience included 380 patients who were enrolled in a prospective, observational, multicenter, and open-label study to receive 16 mg/day of galantamine and 30 mg/day of memantine for 12 months of treatment of addition.


      The therapeutic response was measured using the Mini Mental State Examination (MMSE), Clinical Dementia Rating (CDR), Alzheimer's Disease Assessment Scale (ADAS-GOG), Functional Activities Questionnaire (FAQ) the Clinical Global Impression Scale (CGI) and the UKU scale of adverse effects taking into account the efficacy, safety and adverse events of the treatment.


      The final results of the study showed that galantamine with addition memantine improves cognition, behavioural symptoms, and the general well-being of patients with cognitive impairment: Alzheimer's disease. The incidence of adverse events was not significant and a very good profile of tolerability and safety was observed.

      Authors’ Affiliations

      Servicio de Psiquiatría, Hospital Italiano de La Plata
      Servicio de Salud Mental, Hospital Centenario


      1. Blesa R: Galantamine: therapeutics effects beyond cognition. Dement Geriatr Cogn Disord. 2000, 11 (suppl 1): 28-34. 10.1159/000051229.View ArticlePubMed
      2. Sramek JJ, Veroff AE, et al: The status of ongoing trials for mild cognitive impairment. Expert Opin Inveting Drugs. 2001, 10 (4): 741-752. 10.1517/13543784.10.4.741.View Article


      © Zarra et al; licensee BioMed Central Ltd. 2009

      This article is published under license to BioMed Central Ltd.